Menu Search
Equities

Sun Pharmaceutical Industries Ltd

SUNPHARMA:NSI

Sun Pharmaceutical Industries Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,780.95
  • Today's Change10.15 / 0.57%
  • Shares traded55.48k
  • 1 Year change+47.99%
  • Beta0.7890
Data delayed at least 15 minutes, as of Nov 22 2024 04:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy10
Outperform12
Hold8
Sell3
Strong Sell0

Share price forecast in INR

The 33 analysts offering 12 month price targets for Sun Pharmaceutical Industries Ltd have a median target of 2,040.00, with a high estimate of 2,450.00 and a low estimate of 1,331.00. The median estimate represents a 15.20% increase from the last price of 1,770.80.
High38.4%2,450.00
Med15.2%2,040.00
Low-24.8%1,331.00

Dividends in INR

In 2024, Sun Pharmaceutical Industries Ltd reported a dividend of 13.50 INR, which represents a 17.39% increase over last year. The 23 analysts covering the company expect dividends of 14.02 INR for the upcoming fiscal year, an increase of 3.85%.
Div growth (TTM)17.39%
More ▼

Earnings history & estimates in INR

On Oct 28, 2024, Sun Pharmaceutical Industries Ltd reported 2nd quarter 2025 earnings of 12.70 per share. This result exceeded the 11.62 consensus of the 6 analysts covering the company and exceeded last year's 2nd quarter results by 28.28%.
The next earnings announcement is expected on Jan 29, 2025.
Average growth rate+6.45%
Sun Pharmaceutical Industries Ltd reported annual 2024 earnings of 41.96 per share on May 22, 2024.
Average growth rate+28.63%
More ▼

Revenue history & estimates in INR

Sun Pharmaceutical Industries Limited had 2nd quarter 2025 revenues of 132.91bn. This missed the 133.30bn consensus estimate of the 17 analysts following the company. This was 11.31% above the prior year's 2nd quarter results.
Average growth rate+2.24%
Sun Pharmaceutical Industries Limited had revenues for the full year 2024 of 484.97bn. This was 10.51% above the prior year's results.
Average growth rate+10.36%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.